Live US midterm elections results
The latest updates on the races that will shape the balance of power in Washington
The latest updates on the races that will shape the balance of power in Washington
Figure underscores resilience despite surging energy prices and rising borrowing costs.
Move comes after lender launched third redundancy round in three years in January
AI; US; work; ‘Spoons; Wood; planes; curry
Stock sinks almost 9 per cent after-market as chief executive’s fate hangs in balance following more revelations
The inside story on the Asia tech trends that matter, from Nikkei Asia and the Financial Times
Chip giant co-founder’s future as chief executive is uncertain following report of a second affair
A dialogue with Adam Josephson of Sakonnet Research
Also in this letter: Milan property corruption case collapses, but stains remain
There aren’t enough baskets to safely cope with this many massive eggs
Sonja Hutson speaks to Jon Foley, Henry Foy and Barney Jopson
Also in today’s newsletter: Jamie Raskin interview and race for ECB president
The start-up is forging ahead with its listing in the face of adversity for the broader AI trade
Latest withdrawal from influential industry rankings follows similar moves by Kirkland & Ellis and Paul Weiss
Boost in shipments expected to be shortlived after Ukraine resumes attacks on refineries
Pablo Hernández de Cos’s bid gains momentum as Paris and Berlin eye package deal on central bank leadership
Gideon speaks to Robin Niblett
European carmakers had warned the levy would make them more vulnerable to Chinese competition
You don’t have to be a libertarian nut job to acknowledge the costs imposed by the US administrative state
Electricity providers are leading the business presence at COP31
Diane Morgan’s clueless creation is as gloriously silly as ever as she ponders what AI means for the future of Hollywood
President Nicușor Dan says his country wants ‘more American troops and more lethal capabilities’
The current extreme risk-taking in equity markets might present a once-in-a-career investment opportunity
Financial backers are wary of the pioneering medical treatment as it does not have the same economies of scale as traditional drugs